Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

ImmunoGen Culls 220 Employees

ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.

Read More »

FDA advisory panel votes against Daiichi Sankyo’s blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration voted against Daiichi Sankyo Co. Ltd.’s treatment for adults with a type of acute myeloid leukemia.

Read More »

FDA puts partial clinical study hold on Venclexta

The U.S. Food and Drug Administration placed a partial clinical hold on all trials of AbbVie’s Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the cancer drug arm of the late-stage study.

Read More »

Investing Into R&D Pays off for Some of Biotech’s Biggest Companies

PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.

Read More »

Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines

Pfizer Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union.

Read More »

Teva’s Job Cuts Hit 208 Philadelphia Employees

Cuts implemented by Israel-based Teva Pharmaceutical hit the shores of the United States. The company is laying off 208 people in the Philadelphia area.

Read More »

U.S. FDA Approves Teva’s Trisenox

Trisenox (arsenic trioxide) injection was approved in combination with tretinoin for treating adults with newly diagnosed low-risk acute promyelocytic leukemia.

Read More »

J&J Terminates Two Drugs From Pipeline

Johnson & Johnson indicated in its third-quarter 2017 financial announcement that the company is dropping two of its pipeline drugs.

Read More »

Mateon Therapeutics Cuts 60 Percent of Jobs

Following a failure to determine clear efficacy in its experimental combo ovarian cancer drug, Mateon ended the drug program and cut 60% of its employees.

Read More »

Death puts Cellectis cell therapy tests on hold

French cell therapy specialist Cellectis, which is developing a gene-modified cancer treatment, was forced to suspend testing following a patient death.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom